Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar’s Top 100 Emerging Biotech Start-ups report showcases 100 of the most exciting early-stage companies that are currently developing therapeutics for major health challenges globally. The companies […]
We featured eight biotech startups in the last three month of 2021, working on a range new approaches to tackling major diseases. You can find out more about the companies in the summaries below, or go to the VentureRadar Database to find thousands more biotech companies similar to these ones. Resalis Therapeutics Resalis Therapeutics is […]
In the past three months we’ve featured 11 biotech startups, working on a range new approaches to tackling major diseases. You can find out more about the startups in the summaries below, or head across to the VentureRadar Database to find thousands more biotech companies like these ones. Ancilia Biosciences Ancilia Biosciences develops novel bacterial […]
In the past three months we’ve featured 11 emerging biotech startups — selected from the VentureRadar Database — working on a range new approaches to tackling major diseases. You can find out more about all the companies in the summaries below. Cutanos Cutanos is developing dermal targeted delivery systems for novel vaccines and immunotherapies via […]
In the first three months of 2021 we’ve featured 11 new biotech companies. Below is the full list. You can also head over to the VentureRadar Database to find 1000s of similar biotech startups. Dunad Therapeutics Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies, which it […]
We featured 10 biotech startups on Startups.Bio during the final quarter of 2020. Below is the full list. You can also head over to the VentureRadar Database to find 1000s of similar companies. Ambagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagon says its approach opens […]